The cost of immunotherapy with Keytruda (Pembrolizumab) in Ukraine generally ranges from $4,500 to $8,000. Prices vary depending on the clinic, the oncologist’s experience, the number of treatment cycles, and whether Keytruda is combined with other therapies. In the United States, the average cost is $21,500 (per NCCN). That means immunotherapy with Keytruda in Ukraine can be about 71% less than in the U.S.
Ukrainian clinics usually include the cost of the Keytruda drug, oncologist consultations, infusion sessions, basic pre-treatment bloodwork, and routine follow-ups. In the U.S., drug costs, infusion fees, and lab work are often billed separately. Always confirm if extra tests, imaging, or supportive medications are covered in your treatment package.
| Ukraine | Turkey | Austria | |
| Immunotherapy with Keytruda (Pembolizumab) | from $4,500 | from $7,300 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy with Keytruda (Pembolizumab) upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy with Keytruda (Pembolizumab) and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy with Keytruda (Pembolizumab) journey.
Dobrobot is a network of private multispecialty clinics in Kyiv, Ukraine.
Medical centers specialize in 75 branches. The main ones are oncology, cardiac surgery, endovascular surgery, plastic surgery, orthopedics and traumatology.
Dobrobut surgeons perform more than 11,000 operations per year.
Over 330,000 patients undergo treatment annually.
Day 1
Day 2
Day 3
Day 4-5
Day 6
Day 7
Weeks 2-4
Please note that each patient"s experience may vary, and you should always follow the advice of your healthcare provider.
Keytruda, a form of immune-based therapy, leverages the body's immune system to target and destroy cancer cells using monoclonal antibodies.